08 November 2019 | Senza categoria
PharmaNutra was exhibiting at CPhI Worldwide 2019 in Frankfurt
CPhI Worldwide 2019 was held from 5ᵗʰ to 7ᵗʰ November: three days dedicated to the best of global pharma, during which PharmaNutra presented its more recent scientific novelties to international partners.
The thirtieth edition of CPhI Worldwide, the pharmaceutical sector’s most important international fair, ended yesterday after bringing together 45,000 participants.
Exhibiting for the second time, PharmaNutra reaped considerable success in terms of visibility and people visiting the stand; consistent with the fair’s growth trend – in both participation and importance – as it represents the best of the entire pharmaceutical production chain.
Present in Germany, the President of PharmaNutra S.p.A. Andrea Lacorte, the COO, Carlo Volpi and the Chief Scientific Officer, Germano Tarantino, together with the R&D team and the Group’s foreign department.
“CPhI is a very important event. It not only creates an opportunity to establish business contacts with companies and professional from all over the world, but is also useful for meeting our foreign partners. Compared to our first time exhibiting, in 2018, during this edition we undoubtedly found that the company’s reputation is growing. We are already present successfully in more than 50 countries which is definitely an indicator of reliability”, comments the President, Andrea Lacorte.
“We have several foreign market objectives, both short and medium-long term”, declares the Group’s COO, Carlo Volpi. “On the one hand, all the partners we are collaborating with are growing with the current product portfolio. The next step will be to expand the commercial offer in single Countries, starting with Cetilar®, ApportAL® and UltraMag®. On the other, between 2020 and the start of 2021, commercialisation will be starting in all the Countries with which we have recently signed distribution agreements. In addition to collaboration following contacts started during this CPhI 2019. We expect to end the year with significant growth and for that to continue over the next few years”.
From the scientific development point of view, during the three CPhI 2019 days the Group’s R&D department presented the results of new research on both of the company’s flagship lines.
“For Cetilar®, we have recently published a study on professional athletes, focussed in a daily combined use of Cetilar® Cream and Cetilar® Patch during the rehabilitation stage. For SiderAL®, we have presented evidence on the basic research and action mechanism of Sucrosomial® Iron, together with the clinical studies discussed during the last IMCID (International Multidisciplinary Course on Iron Deficiency) held in Rome last March”, says Germano Tarantino, Chief Scientific Officer of PharmaNutra.
A highly positive outcome enabling the company to focus on the next events in 2020, anticipated by the President, Lacorte: “From 12ᵗʰ to 14ᵗʰ May we will be returning to Vitafoods Europe in Geneva. Then we will be concentrating on CPhI Worldwide 2020, to be held from 13ᵗʰ to 15ᵗʰ October in Milan: playing on home ground we cannot but hope to have an even more prestigious event space”.